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ABSTRACT
Objectives To evaluate the protein expression of
connexin 43 (Cx43) in primary urothelial bladder cancer
and test its association with the histopathological
characteristics and clinical outcome.
Methods A tissue microarray containing 348 tissue
samples from 174 patients with primary urothelial
carcinomas of the bladder was immunohistochemically
stained for Cx43. The intensity of staining was
semiquantitatively evaluated (score 0, 1+, 2+), and the
association with clinicopathological features was
assessed. Univariable and multivariable analyses were
performed to identify predictors for progression-free
survival (PFS).
Results Membranous Cx43 immunoreactivity was
detected in 118 (67.8%) of 174 analysable urothelial
carcinomas, of which 31 (17.8%) showed even a strong
(score 2+) and mainly homogeneous staining. Strong
expression levels of Cx43 (score 2+) were associated
with higher tumour grade, multiplicity and increased
proliferation (all p<0.05). In the subgroup of patients
with stage pTa and pT1 bladder tumours (n=158),
strong Cx43 expression (p<0.001), solid growth pattern
(p<0.001) and increased Ki-67 proliferation fraction
(p<0.05) were signiﬁcantly associated with shorter PFS
in an univariable Cox regression analysis. In multivariable
Cox regression models, Cx43 immunoreactivity and
histological growth pattern remained highly signiﬁcant
and adverse risk factors for PFS.
Conclusions The expression levels of Cx43 are
frequent in non-muscle invasive bladder cancer (NMIBC),
with high expression levels being associated with poor
prognosis. Routine assessment of Cx43 expression may
improve the identiﬁcation of high-risk NMIBC.
INTRODUCTION
Despite improvements in diagnosis and manage-
ment of urothelial bladder cancer (BC), the risk of
tumour progression and recurrence remains a rele-
vant problem. Patients with primary BC initially
present mostly with non-muscle invasive bladder
cancer (NMIBC) with either papillary non-invasive
(pTa) or early invasive (pT1) urothelial carcinoma
(70–80%), whereas the remaining 20–25% of
primary tumours are already muscle invasive
(≥pT2) at ﬁrst diagnosis.1 2 Among NMIBC, almost
70% recur after initial transurethral resection and
up to 25% show progression into muscle-invasive
disease.3 Currently, the risk of recurrence and pro-
gression is assessed by clinicopathological factors.4
However, clinical and pathological parameters
cannot accurately predict individual disease courses.
Therefore, patients still need to be closely moni-
tored to detect tumour recurrence and progression,
leading to high healthcare costs of this disease.5
Markers that can diagnose NMIBC with a high risk
of progression are needed for better and more spe-
ciﬁc surveillance strategies.6 Despite decades of
research for biomarkers that allow a valid prediction
of NMIBC progression,7–10 none are routinely used
in clinical practice.
Cell migration is a fundamental process and is
essential for many physiological functions of the
organism. In addition, cell migration has an active
role in pathophysiological processes such as tumour
growth and the ability to metastasise.11 12 Several
proteins are involved in cell migration or its modula-
tion; these include connexins (Cxs), which are con-
sidered to compose gap junctions to form
intercellular channels.13 14 The channels composed
by Cxs serve as selective gates for the transport of
small molecules such as growth factors, second mes-
senger molecules or ions between cells.15 Cxs are
therefore essential for cell homoeostasis and play an
important role in the regulation of proliferation, cell
growth and apoptosis.16 17 Cxs comprises a family
of more than 20 proteins. One of the most studied
Cx proteins is Cx 43 (Cx43).18 19 Cx43 is expressed
in most epithelial tissues. Previous studies showed
reduced Cx43 expression in cancerogenesis and
therefore Cx43 was initially thought to have only a
tumour suppressor role.20–22 However, there is
growing evidence that Cx43 is involved in cancer
development and metastatic processes and overex-
pressed in invasive lesions of some solid tumours
such as breast or colon cancer.23–25
A broad expression analysis of Cx43 in urothelial
carcinomas has not been conducted so far and
there are no studies available on the prognostic
relevance of Cx43 in BC. We aimed to analyse the
expression patterns of Cx43 in a fairly large cohort
of primary BCs and correlated these to clinico-
pathological parameters including tumour stage,
grade, multifocality, adjacent carcinoma in situ,
growth pattern and ﬁnally, disease course.
METHODS
BC tissue microarray
Tissue microarrays (TMAs) contained 348 forma-
lin-ﬁxed, parafﬁn-embedded urothelial BC tissues
from 174 patients and were constructed as
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previously described.26 All tumour samples were represented in
duplicate tissue cores (diameter 1 mm). Specimens were col-
lected between 1990 and 2006 by the Institute of Surgical
Pathology, University Hospital Zurich, Switzerland. TMA
includes a series of 174 consecutive (non-selected) primary
urothelial bladder tumours. Finally, TMA contained 90 pTa, 68
pT1 and 16≥pT2 tumours. H&E-stained slides of all specimens
were re-evaluated by a board-certiﬁed pathologist (PJW).
Tumour stage and grade were assigned according to Union for
International Cancer Control (UICC) and WHO criteria.
Retrospective clinical follow-up data were available for all the
174 patients (100%). The median follow-up period for the
entire cohort was 110.6 months (range 32.4–266.8 months).
Adjuvant bladder installation therapy (BCG or chemotherapy)
could not be evaluated properly due to missing data in about
50% of the patients. Clinicopathological data are summarised in
table 1. TMA and associated clinicopathological data have been
previously published.27
Immunohistochemistry
TMA was freshly cut and was used on 3 mm parafﬁn sections, as
described previously.28 Additionally, to analyse the immunoreactiv-
ity of Cx43 in non-dysplastic urothelium, eight slides were cut
from formalin-ﬁxed, parafﬁn-embedded urothelium of the bladder
neck of patients without any history of urothelial dysplasia or BC.
For immunohistochemical detection of Cx43 on tissue samples,
antihuman Cx43 antibody from Sigma (C6219, dilution 1:200)
was used. Ki-67 was detected with clone Molecular Immunology
Borstel-1 (MIB-1) (dilution 1:50; Dako, Glostrup, Denmark).
Immunohistochemical studies used an avidin-biotin peroxidase
method with a diaminobenzidine chromatogen. After antigen
retrieval (microwave oven for 30 min at 250 W), immunohisto-
chemistry was conducted using an autostainer (Ventana, Tucson,
Arizona, USA) following the manufacturer’s instructions.
Evaluation of immunohistochemistry
Slides were evaluated by two experienced pathologists (LB,
PJW). Immunoreactions for Cx43 were evaluated using a semi-
quantitative three-scale scoring system by considering scores
0–2+, in which score 0: no staining; score 1+: weak staining;
score 2+: strong staining. For statistical analysis, cases exhibiting
a score of 0 or 1+ were pooled in a Cx43 low-expression group,
whereas cases with a score of 2+ were categorised in a Cx43
high-expression group. The percentage of Ki-67 positive cells of
each specimen was determined as described previously.29 High
Ki-67 labelling index was deﬁned as more than 10% of positive
tumour cells.30 If different staining intensity was observed
between the duplicate tissue cores, the core with more represen-
tative tumour tissue was chosen. If both duplicate cores showed
equal amounts of representative tumour tissue, the intensity of
the core with more homogenous staining intensity was selected.
Statistical analysis
Statistical analyses were performed with the survival package in
R V.3.0.3 (http://www.r-project.org) and SPSS V.22.0 (SPSS,
Chicago, Illinois, USA). Differences were considered statistically
signiﬁcant if p<0.05. To study statistical associations between
clinicopathological and immunohistochemical data, contingency
table analysis and two-sided Fisher’s exact tests were used.
Univariable and multivariable Cox regression analyses were used
to evaluate statistical association between clinicopathological/
immunohistochemical data and progression-free survival (PFS)
and recurrence-free survival (RFS). The assumptions of propor-
tional hazards were satisﬁed in the Cox regression model and
were graphically assessed by looking at the log-minus-log plot.
All variables in the multivariable model were added in one
single step (enter method). Harrel’s concordance index
(c-index) was calculated to assess predictive accuracy.
PFS and RFS curves were calculated using the Kaplan-Meier
method with signiﬁcance evaluated by two-sided log-rank statis-
tics and were plotted with pointwise bands at a conﬁdence level
of 0.95. For the analysis of PFS in NMIBC, patients were cen-
sored at the date when there was a stage-shift (from pTa to
pT1–T4 or from pT1 to pT2–T4), or if a distant metastasis was
detected. Grade progression (low grade (or G1–2) to high grade
(G3)) without stage-shift was not considered as progression. For
the analysis of RFS, patients were censored at the date when
there was a recurrent and histologically proven tumour in the
bladder. Any positive resection or another transurethral resec-
tion of the bladder (TUR-B) within 3 months after primary
TUR-B was not considered as recurrence but residual tumour.
Table 1 Patient and tumour characteristics and results of
molecular and immunohistochemical analyses
Variable Categorisation n analysable* Per cent
Total (n=174)*
Clinicopathological data
Age at diagnosis (median, range) 69.5 years (32–92)
<70 years 87 50.0
≥70 years 87 50.0
Sex
Female 43 24.7
Male 131 75.3
Tumour stage48†
pTa 90 51.7
pT1 68 39.1
pT2 13 7.5
pT3 2 1.1
pT4 1 0.6
Histological grade48†
G1 44 25.3
G2 87 50.0
G3 43 24.7
Histological grade49‡
Low grade 101 58.0
High grade 73 42.0
Adjacent carcinoma in situ
No 158 90.8
Yes 16 9.2
Multiplicity
Solitary 124 71.3
Multifocal 50 28.7
Growth pattern
Papillary 159 91.4
Solid 15 8.6
Immunohistochemistry (IHC)
Cx43
Score 0 56 32.2
Score 1+ 87 50.0
Score 2+ 31 17.8
Ki67 labelling index
≤10% 108 62.1
>10% 66 37.9
*All patients.
†Staging and grading according to the 1973 WHO classification system.
‡Staging and grading according to the 2004 WHO classification system.
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RESULTS
Staining patterns of Cx43
Cx43 protein expression in BC tissue samples was investigated
by immunohistochemical analysis of TMA containing 174 speci-
mens from patients with primary urothelial carcinoma of the
bladder. All 174 (100%) patients could be evaluated for Cx43
immunostaining.
Cx43 immunoreactivity mainly showed a homogeneous mem-
branous staining in 170 of 348 TMA spots (48.9%). A relatively
small proportion of the investigated tumours showed Cx43
immunoreactivity only in the intermediate and upper layers
(n=52, 14.9%), whereas a few cases were found to have Cx43
expression only in the basal layer (n=9, 2.6%). Figure 1A repre-
sents a tumour tissue example of Cx43 negative staining
(score 0). Figure 1B shows an example of weak Cx43 staining
(score 1+), whereas ﬁgure 1C depicts a typical example of strong
Cx43 staining (score 2+) in the plasma membrane of the tumour
cells.
Strong expression levels of Cx43 (score 2+) were found in
31 of 174 patients (17.8%). Eighty-seven (50%) of the other
tumours showed weak expression levels (score 1+) of Cx43,
and 56 (32.2%) were found to have no staining (score 0) for
Cx43. All other clinicopathological data are summarised in
table 1.
In non-dysplastic urothelium of the bladder neck of indivi-
duals without any previous history of bladder dysplasia or
cancer, seven out of eight samples showed a weak but consistent
Cx43 protein expression in the basal and intermediate layers
(see online supplementary ﬁgure S1A–F) as well as in Brunn’s
nests (see online supplementary ﬁgure S1G). Another single
sample showed a strong Cx43 staining intensity (see online sup-
plementary ﬁgure S1H). Urothelial umbrella cells at the surface
were negative for Cx43 in all normal cases.
Correlation of Cx43 expression with
clinicopathological parameters
Cx43 was correlated with clinicopathological characteristics
(stage, grade, adjacent carcinoma in situ, multiplicity, growth
pattern and Ki-67) of the tumours (table 2). Strong staining
of Cx43 was associated with higher grade49 (p=0.026) and
multiplicity (p=0.004). Moreover, strong staining of Cx43 was
signiﬁcantly associated with high Ki-67 labelling index
(p=0.014). High Ki-67 labelling index showed a signiﬁcant cor-
relation with all clinicopathological characteristics (p<0.05),
except for tumour multiplicity (data not shown). Results of
clinicopathological and Ki-67 label index of this TMA have
been previously published.27
Prognostic potential of Cx43 in primary pTa and pT1
urothelial tumours
A total of 158 patients underwent TUR for a primary pTa or
pT1 urothelial carcinoma of the bladder and were followed for
a median of 110.7 months (range: 32.4–245.9 months). From
the 158 NMIBC cases, 22 (13.9%) cases showed progression
Figure 1 Immunohistochemical staining with Cx43: An example of negative staining Score 0 (A) and weak (score 1+) staining pattern (B) of the
Cx43 protein; Strong staining (score 2+) pattern (C) of Cx43.
Table 2 Comparison of the molecular and immunohistochemical
markers with pathological characteristics (n=174)
Variable Categorisation
Cx43 expression
Score 0 or 1+ Score 2+ p Value
Tumour stage48†
pTa 76 (84) 14 (16) 0.815
pT1 54 (79) 14 (21)
pT2 10 (77) 3 (23)
pT3 2 (100) 0 (0)
pT4 1 (100) 0 (0)
Histological grade48†
G1 40 (91) 4 (9) 0.195
G2 68 (78) 19 (22)
G3 35 (81) 8 (19)
Histological grade49‡
Low grade 89 (88) 12 (12) 0.026
High grade 54 (74) 19 (26)
Adjacent carcinoma in situ‡
No 128 (81) 30 (19) 0.311
Yes 15 (94) 1 (6)
Multiplicity‡
Solitary 109 (88) 15 (12) 0.004
Multifocal 34 (68) 16 (32)
Growth pattern‡
Papillary 130 (82) 29 (18) 1.000
Solid 13 (87) 2 (13)
Immunohistochemistry
Ki-67 labelling index
≤10% 95 (88) 13 (12) 0.014
>10% 48 (73) 18 (27)
Data are presented as numbers (percent).
†χ2 Pearson (two-sided); bold face representing p values <0.05.
‡Fisher’s exact test (two-sided); bold face representing p values <0.05.
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(median time to progression was 45.2 months (range 10.2–
226.7 months)), and 26 (16.5%) patients died during follow-up.
In this group, high expression levels (score 2+) of Cx43 were
signiﬁcantly associated with increased risk of progression
(p<0.001). Aside from the growth pattern (p<0.001) and
Ki-67 (p=0.003), none of the other clinicopathological para-
meters were signiﬁcantly associated with PFS. Table 3 shows
p values for the pathological data and the molecular markers.
We performed univariable and multivariable Cox regression
analyses. In univariate analysis, strong Cx43 expression
(p<0.001), solid growth pattern (p<0.001) and Ki-67
(p=0.006) were signiﬁcantly associated with reduced PFS.
Additionally, grading49 showed a trend for reduced PFS
(p=0.09). All four variables were included in a multivariable
Cox regression analysis. Strong staining of Cx43 (p<0.001;
HR 7.754 (95% CI 2.763 to 21.76)) and solid growth
pattern (p<0.001; HR 13.377 (95% CI 3.314 to 53.99))
remained independent predictors for shorter PFS (table 4).
Kaplan-Meier analyses for PFS and RFS depicted in ﬁgures
2A, B, respectively, show that patients with strong Cx43
immunoreactivity have a signiﬁcantly shorter PFS and RFS
than patients with weak or negative staining for Cx43. The
clinical beneﬁt was moreover conﬁrmed by analysing the
C-index in the multivariable Cox regression model. The
C-index was higher using the multivariable model with Cx43
than without (C-index with Cx43: 0.813; C-index without
Cx43: 0.723).
In a descriptive subgroup analysis for patients with pT1 high
grade tumours (n=40) strong Cx43 expression (p=0.024) was
signiﬁcantly associated with reduced PFS (see online supplemen-
tary ﬁgure S2A). Strong Cx43 immunoreactivity (p=0.257) was
not associated with shorter RFS in this subgroup analysis
(see online supplementary ﬁgure S2B).
DISCUSSION
This is the ﬁrst study analysing immunohistochemical Cx43
expression in primary BC and its association with prognosis. In
our study, we found that Cx43 was highly expressed in 31 out
of 174 investigated urothelial tumours. Strong Cx43 staining
was associated with higher grade, multifocal tumours and
increased Ki-67 labelling index. Furthermore, high expression
levels of Cx43 were found to be an independent predictor of
PFS in NMIBC. Our ﬁndings suggest that Cx43 may play a role
in the prognosis of patients with non-muscle invasive urothelial
tumours.
So far, only two studies have investigated the role of Cx26
in BC and both have found an overexpression of Cx26 in
human BC and an association with adverse pathological fea-
tures.31 32 Another study, by Corteggio et al,33 examined the
expression levels of Cx43 in bovine urothelium and bovine
urothelial cancer. The authors found that Cx43 was expressed
in normal urothelium, papillary neoplasms and carcinoma in
situ, but not in invasive urothelial cancer. In addition, Cx43
has been found to be altered in the detrusor muscle of the
bladder in patients with overactive bladder syndrome or inter-
stitial cystitis.34 35
Cx43 expression is upregulated in various other tumour entities,
including glioma, colon cancer and invasive breast cancer.24 36 37
In contrast, several studies have reported the downregulation of
Table 3 Analysis of factors for tumour progression
Variable Categorisation
Tumour progression (TP)
n* Events p Value†
Pathological data
Tumour stage48‡
pTa 90 10 0.360
pT1 68 12
Histological grade48‡
G1 44 3 0.085
G2 86 12
G3 28 7
Histological grade49§
Low grade 99 10 0.083
High grade 59 12
Adjacent carcinoma in situ
No 146 20 0.545
Yes 12 2
Multiplicity
Unifocal tumour 115 15 0.465
Multifocal tumour 43 7
Growth pattern
Papillary 151 17 <0.0001
Solid 7 5
Immunohistochemistry
Cx43
Score 0 or 1+ 130 12 <0.0001
Score 2+ 28 10
Ki-67 labelling index
≤10% 106 9 0.003
>10% 52 13
*Only primary pTa and pT1 tumours are included.
†Log-rank test (two-sided); bold face representing p values <0.05.
‡Staging and grading according to the 1973 WHO classification system.
§Staging and grading according to the 2004 WHO classification system.
Table 4 Univariable and multivariable Cox regression analyses for tumour progression
Variable Categorisation
Univariable analysis Multivariable analysis
HR 95% CI p Value HR 95% CI p Value
Tumour stage (pTa vs pT1) 1.481 0.635 to 3.454 0.363
Histological grade49* 2.072 0.894 to 4.804 0.09 0.706 0.258 to 1.933 0.499
Adjacent carcinoma in situ 1.563 0.363 to 6.723 0.549
Multifocality 1.401 0.565 to 3.472 0.467
Growth pattern (papillary vs solid) 7.653 2.715 to 21.568 <0.001 13.377 3.314 to 53.99 <0.001
Cx43 5.266 2.224 to 12.467 <0.001 7.754 2.763 to 21.76 <0.001
Ki-67 3.36 1.428 to 7.904 0.006 1.76 0.627 to 4.941 0.283
*Staging and grading according to the 2004 WHO classification system.
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Cx43 in solid tumours; for example, in ovarian cancer, non-
melanotic skin tumours and lung cancer.38–40
The role of Cxs in tumours and in cancer progression
seems to be controversial. This may be due to cellular hetero-
geneity of the analysed tumours and the complex multilevel
process of tumorigenesis and progression. However, more
reports suggest that Cx43 is overexpressed in some solid
tumours and is involved in late metastatic steps. This could be
demonstrated for breast cancer, melanoma and oral squamous
cell carcinoma.25 41 42
As previously published, increased proliferation as assessed by
Ki-67 was highly associated with tumour grade, stage and
shorter PFS in this cohort.27 The prognostic role of Ki-67 in
urothelial cancer and its association with pathological para-
meters and prognosis has already been shown in several
studies.43 44 Here, we observed a signiﬁcant correlation between
the proliferation index (Ki-67) and Cx43 (p=0.014).
As the proportion of muscle-invasive BC samples was limited,
we cannot draw any conclusions for this group of tumours. The
prognostic role in locally advanced invasive BC has to be evalu-
ated in further studies with higher sample sizes.
Our results demonstrate the potential diagnostic value of
Cx43 for the assessment of progressive primary NMIBC. Our
ﬁndings suggest that the overexpression of Cx43 in BC facili-
tates tumour cell survival and progression by enhanced gap junc-
tion activity, which has previously been shown to induce
tumour growth and tumour cell survival.45–47 In addition to its
prognostic signiﬁcance, speciﬁc pharmaceutical or genetic
approaches to inhibit Cx43 activity may provide ways to reduce
progression in NMIBC.
CONCLUSION
Positive immunoreactivity of Cx43 is frequently observed in BC
and showed a signiﬁcant correlation with different clinicopatho-
logical variables in BC.
High expression levels of Cx43 were associated with poor
prognosis in NMIBC. Routine assessment of Cx43 expression
may improve the identiﬁcation of high-risk NMIBC. Further
prospective studies and larger cohorts are needed to conﬁrm the
prognostic impact of Cx43 in BC.
Take home messages
▸ Besides clinicopathological parameters no biomarkers are
established to assess prognosis in primary bladder cancer (BC).
▸ Connexin 43 (Cx43) has been proposed to be involved in
cancer development in solid tumours such as breast cancer
or colon cancer.
▸ This is the ﬁrst study demonstrating the prognostic value of
immunohistochemical Cx43 expression in primary
non-muscle invasive BC.
▸ Strong Cx43 protein expression was associated with worse
clinicopathological features and was furthermore an
independent risk factor for shorter progression-free survival.
▸ Routine assessment of Cx43 expression may improve the
identiﬁcation of high-risk non-muscle invasive BC.
Handling editor Cheok Soon Lee
Contributors Conception and design: CP, LB, PJW. Provision of study materials or
patients: CP, TH, AH, JR, LB, HM. Collection and assembly of data: AH, DM, CP.
Data analysis/interpretation: CP, LB, FR, MD, PJW, TS, QZ. Manuscript writing: CP,
LB, PJW. Final approval of manuscript: CP, LB, FR, MD, TH, DM, AH, JR, QZ, TS,
HM, PJW.
Competing interests None declared.
Ethics approval Cantonal Scientiﬁc Ethics Committee Zurich (http://www.kek.zh.
ch/, approval no.: StV-Nr. 25/2007).
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International
Society of Urological Pathology consensus classiﬁcation of urothelial (transitional
cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.
Am J Surg Pathol 1998;22:1435–48.
Figure 2 Kaplan-Meier analyses for progression-free survival (A) and for recurrence-free survival (B) for Cx43 staining (n=158). For statistical
analysis for survival curves log-rank test was used. Pointwise bands at a conﬁdence level of 0.95 were computed. N-values represent the number of
patients in each group.
Poyet C, et al. J Clin Pathol 2015;0:1–6. doi:10.1136/jclinpath-2015-202898 5
Original article
group.bmj.com on August 17, 2015 - Published by http://jcp.bmj.com/Downloaded from 
2 Sanchez-Carbayo M, Socci ND, Lozano J, et al. Deﬁning molecular proﬁles of poor
outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
J Clin Oncol 2006;24:778–89.
3 Lapham RL, Ro JY, Staerkel GA, et al. Pathology of transitional cell carcinoma of
the bladder and its clinical implications. Semin Surg Oncol 1997;13:307–18.
4 Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and
progression in individual patients with stage Ta T1 bladder cancer using EORTC risk
tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol
2006;49:466–5; discussion 75–7.
5 Svatek RS, Hollenbeck BK, Holmang S, et al. The economics of bladder
cancer: costs and considerations of caring for this disease. Eur Urol
2014;66:253–62.
6 Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the
management of muscle-invasive bladder cancer. Lancet Oncol 2002;3:738–47.
7 Wild PJ, Herr A, Wissmann C, et al. Gene expression proﬁling of progressive
papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res
2005;11:4415–29.
8 Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, et al. Cathepsin E, maspin, Plk1,
and survivin are promising prognostic protein markers for progression in non-muscle
invasive bladder cancer. Am J Pathol 2012;180:1824–34.
9 Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53
protein in transitional cell bladder carcinoma: a marker for disease progression.
J Natl Cancer Inst 1993;85:53–9.
10 Cordes I, Kluth M, Zygis D, et al. PTEN deletions are related to disease progression
and unfavourable prognosis in early bladder cancer. Histopathology
2013;63:670–7.
11 Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and
cancer. Nat Rev Mol Cell Biol 2009;10:445–57.
12 O’Hayre M, Salanga CL, Handel TM, et al. Chemokines and cancer: migration,
intracellular signalling and intercellular communication in the microenvironment.
Biochem J 2008;409:635–49.
13 Kumar NM, Gilula NB. The gap junction communication channel. Cell
1996;84:381–8.
14 Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res
2004;62:228–32.
15 Yeager M, Harris AL. Gap junction channel structure in the early 21st century: facts
and fantasies. Curr Opin Cell Biol 2007;19:521–8.
16 Krysko DV, Leybaert L, Vandenabeele P, et al. Gap junctions and the propagation of
cell survival and cell death signals. Apoptosis 2005;10:459–69.
17 Wei CJ, Xu X, Lo CW. Connexins and cell signaling in development and disease.
Annu Rev Cell Dev Biol 2004;20:811–38.
18 Su V, Lau AF. Connexins: mechanisms regulating protein levels and intercellular
communication. FEBS Lett 2014;588:1212–20.
19 Solan JL, Lampe PD. Connexin43 phosphorylation: structural changes and biological
effects. Biochem J 2009;419:261–72.
20 Zhao W, Han HB, Zhang ZQ. Suppression of lung cancer cell invasion and
metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via
histone acetylation. Int J Biochem Cell Biol 2011;43:1459–68.
21 Langlois S, Cowan KN, Shao Q, et al. The tumor-suppressive function of
Connexin43 in keratinocytes is mediated in part via interaction with caveolin-1.
Cancer Res 2010;70:4222–32.
22 Yamasaki H, Naus CC. Role of connexin genes in growth control. Carcinogenesis
1996;17:1199–213.
23 Pollmann MA, Shao Q, Laird DW, et al. Connexin 43 mediated gap junctional
communication enhances breast tumor cell diapedesis in culture. Breast Cancer Res
2005;7:R522–34.
24 Han Y, Zhang PJ, Chen T, et al. Connexin43 Expression Increases in the Epithelium
and Stroma along the Colonic Neoplastic Progression Pathway: Implications for Its
Oncogenic Role. Gastroenterol Res Pract 2011;2011:561719.
25 Stoletov K, Strnadel J, Zardouzian E, et al. Role of connexins in metastatic breast
cancer and melanoma brain colonization. J Cell Sci 2013;126(Pt 4):904–13.
26 Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for
high-throughput molecular proﬁling of tumor specimens. Nat Med 1998;4:844–7.
27 Poyet C, Jentsch B, Hermanns T, et al. Expression of histone deacetylases 1, 2 and
3 in urothelial bladder cancer. BMC Clin Pathol 2014;14:10.
28 Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3
are highly expressed in renal cell cancer. BMC Cancer 2008;8:381.
29 Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are
highly representative of proliferation index and histological grade. J Pathol
2001;194:349–57.
30 van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell
carcinoma with ﬁbroblast growth factor receptor 3 and MIB-1 is superior to pathologic
grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912–21.
31 Gee J, Tanaka M, Grossman HB. Connexin 26 is abnormally expressed in bladder
cancer. J Urol 2003;169:1135–7.
32 Harris LD, De La Cerda J, Tuziak T, et al. Analysis of the expression of biomarkers
in urinary bladder cancer using a tissue microarray. Mol Carcinog 2008;47:678–85.
33 Corteggio A, Florio J, Roperto F, et al. Expression of gap junction protein connexin
43 in bovine urinary bladder tumours. J Comp Pathol 2011;144:86–90.
34 Sui GP, Coppen SR, Dupont E, et al. Impedance measurements and connexin
expression in human detrusor muscle from stable and unstable bladders. BJU Int
2003;92:297–305.
35 Neuhaus J, Pfeiffer F, Wolburg H, et al. Alterations in connexin expression in the
bladder of patients with urge symptoms. BJU Int 2005;96:670–6.
36 Kanczuga-Koda L, Sulkowski S, Lenczewski A, et al. Increased expression of
connexins 26 and 43 in lymph node metastases of breast cancer. J Clin Pathol
2006;59:429–33.
37 Zhang W, Nwagwu C, Le DM, et al. Increased invasive capacity of connexin43-
overexpressing malignant glioma cells. J Neurosurg 2003;99:1039–46.
38 Umhauer S, Ruch RJ, Fanning J. Gap junctional intercellular communication and
connexin 43 expression in ovarian carcinoma. Am J Obstet Gynecol
2000;182:999–1000.
39 Wilgenbus KK, Kirkpatrick CJ, Knuechel R, et al. Expression of Cx26, Cx32 and
Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer
1992;51:522–9.
40 Jinn Y, Ichioka M, Marumo F. Expression of connexin32 and connexin43 gap junction
proteins and E-cadherin in human lung cancer. Cancer Lett 1998;127:161–9.
41 Haass NK, Ripperger D, Wladykowski E, et al. Melanoma progression exhibits a
signiﬁcant impact on connexin expression patterns in the epidermal tumor
microenvironment. Histochem Cell Biol 2010;133:113–24.
42 Brockmeyer P, Jung K, Perske C, et al. Membrane connexin 43 acts as an
independent prognostic marker in oral squamous cell carcinoma. Int J Oncol
2014;45:273–81.
43 Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1
grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1,
p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol
2004;45:606–12.
44 Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the
prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol
2006;59:83–8.
45 Mendoza-Naranjo A, Saez PJ, Johansson CC, et al. Functional gap junctions
facilitate melanoma antigen transfer and cross-presentation between human
dendritic cells. J Immunol 2007;178:6949–57.
46 Katakowski M, Buller B, Wang X, et al. Functional microRNA is transferred between
glioma cells. Cancer Res 2010;70:8259–63.
47 Laird DW. Life cycle of connexins in health and disease. Biochem J 2006;394
(Pt 3):527–43.
48 Mostoﬁ FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours.
International Classiﬁcation of Tumours, No. 10. Geneva: World Health Organization,
1973:21–31.
49 Eble J, Sauter G, Epstein J, et al. Pathology and Genetics of Tumours of the Urinary
System and Male Genital Organs. Lyon: IARC Press, 2014.
6 Poyet C, et al. J Clin Pathol 2015;0:1–6. doi:10.1136/jclinpath-2015-202898
Original article
group.bmj.com on August 17, 2015 - Published by http://jcp.bmj.com/Downloaded from 
cancer
non-muscle invasive urothelial bladder
progression-free survival in patients with 
Connexin 43 expression predicts poor
Tullio Sulser, Holger Moch and Peter J Wild
Hermanns, Doris Mannhard, Andrej Höhn, Jan Rüschoff, Qing Zhong, 
Cédric Poyet, Lorenz Buser, Filip Roudnicky, Michael Detmar, Thomas
 published online August 6, 2015J Clin Pathol 
 http://jcp.bmj.com/content/early/2015/08/06/jclinpath-2015-202898
Updated information and services can be found at: 
These include:
Material
Supplementary
 C2.html
http://jcp.bmj.com/content/suppl/2015/06/29/jclinpath-2015-202898.D
 C1.html
http://jcp.bmj.com/content/suppl/2015/06/29/jclinpath-2015-202898.D
Supplementary material can be found at: 
References
 #BIBL
http://jcp.bmj.com/content/early/2015/08/06/jclinpath-2015-202898
This article cites 47 articles, 15 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1556)Immunology (including allergy)
 (153)Urological cancer
 (78)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on August 17, 2015 - Published by http://jcp.bmj.com/Downloaded from 
